Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Instagram Outage Disrupts Thousands of U.S. Users 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Cranbury, NJ, May 22, 2017 -- Information on Cornerstone's upcoming presentation at this prestigious industry conference provided below:
WHAT: In partnership with J.P. Morgan, the BioPartnering Conference is expected to bring together over 200 regional biopharmaceutical executives, investors, academic collaborators and business development professionals for a day of networking, 1-1 partnering meetings, company presentations, exhibits and plenary sessions. Sanjeev Luther, Cornerstone’s Chief Operating Officer, will present information on the Company’s novel Altered Energy Metabolism Directed (AEMD) platform, and will provide an update on Cornerstone’s clinical trial development strategy in the wake of the company’s recent announcement that it has received approval from the FDA to conduct pivotal clinical trials in acute myeloid leukemia and pancreatic cancer.
Interviews with Mr. Luther prior to and during the conference are available upon request.
WHERE: Busch Campus Center, Rutgers University; 604 Bartholomew Road – Piscataway, NJ 08854
WHEN: May 23, 2017, 1:45 PM
CONTACT: Jacob Jonas, 973-438-3716 or [email protected], for more information.
About Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. is a clinical-stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Cornerstone’s primary objective is to develop highly selective and effective agents with minimal toxic effects on normal cells and tissues. Cornerstone’s first-in-class clinical lead compound, CPI-613 is being evaluated in multiple Phase I, I/II, and II clinical studies. The U.S. Food and Drug Administration (FDA) has given Cornerstone approval to initiate pivotal clinical trials in pancreatic cancer and acute myeloid leukemia (AML), and has designated CPI-613 an orphan drug for the treatment of pancreatic cancer, AML, and myelodysplastic syndromes (MDS). The company's investors include IDT Corporation (NYSE: IDT). For more information, visit www.cornerstonepharma.com.
